Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.35 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.34 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.34 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.34 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.33 |
| ▸ | VEGFA | P15692 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16126906 | 0.87 | JAK2 (0.39) | CA1CA2JAK2JAK1SLC10A2 | |
| SCHEMBL16126803 | 0.76 | CA1 (0.42) | CA1CA2JAK2JAK1SLC10A2 | |
| SCHEMBL1371402 | 0.67 | PTGDR2 (0.41) | CA1CA2SLC10A2ALDH1A1POLB | |
| SCHEMBL14808551 | 0.66 | CA2 (0.44) | CA1CA2JAK2JAK1SLC10A2 | |
| SCHEMBL25042870 | 0.64 | CA1 (0.42) | CA1CA2SLC10A2ALDH1A1POLB | |
| SCHEMBL31396119 | 0.64 | CA2 (0.40) | CA1CA2SLC10A2CAMK2AVEGFA | |
| SCHEMBL30275162 | 0.64 | CA1 (0.42) | CA1CA2SLC10A2ALDH1A1POLB | |
| SCHEMBL25042684 | 0.64 | CA1 (0.42) | CA1CA2SLC10A2ALDH1A1POLB | |
| SCHEMBL16101715 | 0.62 | CA1 (0.39) | CA1CA2VEGFABACE1BACE2 | |
| SCHEMBL2589648 | 0.62 | VEGFA (0.39) | CA1CA2SLC10A2CAMK2AVEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10059705-B2 | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-08-28 | — | — | US | disclosed |
| EP-2976341-B1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2976341-B1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| EP-2976341-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014146493-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014146493-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | CA1 3144/4885CA2 1790/4885JAK2 2/4885 |
| US-10059705-B2 | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | JAK1, JAK2, JAK3 | CA1 3144/4885CA2 1790/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.